Literature DB >> 21622855

Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice.

Mouna Tabbekh1, Katarzyna Franciszkiewicz, Houda Haouas, Yann Lécluse, Karim Benihoud, Chander Raman, Fathia Mami-Chouaib.   

Abstract

The CD5 coreceptor is expressed on all T cells and on the B1a B cell subset. It is associated with TCR and BCR, and modulates intracellular signals initiated by both Ag receptor complexes. Human CD5 contributes to regulation of the antitumor immune response and susceptibility of specific CTL to activation-induced cell death (AICD) triggered by the tumor. In this study, we compared the T cell response to the B16F10 melanoma engrafted into CD5-deficient and wild-type C57BL/6 mice. Compared with wild-type mice, CD5 knockout animals displayed delayed tumor growth, associated with tumor infiltration by T cell populations exhibiting a more activated phenotype and enhanced antitumor effector functions. However, control of tumor progression in CD5(-/-) mice was transient due to increased AICD of CD8(+) tumor-infiltrating T lymphocytes. Remarkably, in vivo protection of T cells from TCR-mediated apoptosis by an adenovirus engineered to produce soluble Fas resulted in a dramatic reduction in tumor growth. Our data suggest that recruitment of tumor-specific T cells in the tumor microenvironment occurs at early stages of cancer development and that tumor-mediated AICD of tumor-infiltrating T lymphocytes is most likely involved in tumor escape from the immune system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622855     DOI: 10.4049/jimmunol.1004145

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Distinct CD4+ helper T cells involved in primary and secondary responses to infection.

Authors:  K Scott Weber; Qi-Jing Li; Stephen P Persaud; Jeff D Campbell; Mark M Davis; Paul M Allen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

2.  Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.

Authors:  Stephanie K Dougan; Michael Dougan; Jun Kim; Jacob A Turner; Souichi Ogata; Hyun-Il Cho; Rudolf Jaenisch; Esteban Celis; Hidde L Ploegh
Journal:  Cancer Immunol Res       Date:  2013-08       Impact factor: 11.151

3.  Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.

Authors:  Fumihiro Fujiki; Akihiro Tsuboi; Soyoko Morimoto; Naoya Hashimoto; Miki Inatome; Hiroko Nakajima; Jun Nakata; Sumiyuki Nishida; Kana Hasegawa; Naoki Hosen; Yoshihiro Oka; Yusuke Oji; Shinji Sogo; Haruo Sugiyama
Journal:  Cancer Immunol Immunother       Date:  2020-07-22       Impact factor: 6.968

4.  Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.

Authors:  Masayuki Wada; Hongyu Zhang; Liu Fang; Jia Feng; Charlotte Olivia Tse; Wenli Zhang; Qi Chen; Sha Sha; Yuanzhen Cao; Kevin H Chen; Kevin G Pinz; Xi Chen; Xing-Xing Fan; Xun Jiang; Yupo Ma
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

5.  CD5-dependent CK2 activation pathway regulates threshold for T cell anergy.

Authors:  Christine M Sestero; Donald J McGuire; Patrizia De Sarno; Emily C Brantley; Gloria Soldevila; Robert C Axtell; Chander Raman
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

Review 6.  The three as: Alternative splicing, alternative polyadenylation and their impact on apoptosis in immune function.

Authors:  Davia Blake; Kristen W Lynch
Journal:  Immunol Rev       Date:  2021-08-08       Impact factor: 12.988

7.  When Cells Suffocate: Autophagy in Cancer and Immune Cells under Low Oxygen.

Authors:  Katrin Schlie; Jaeline E Spowart; Luke R K Hughson; Katelin N Townsend; Julian J Lum
Journal:  Int J Cell Biol       Date:  2011-11-29

8.  Transgenic expression of soluble human CD5 enhances experimentally-induced autoimmune and anti-tumoral immune responses.

Authors:  Rafael Fenutría; Vanesa G Martinez; Inês Simões; Jorge Postigo; Victor Gil; Mario Martínez-Florensa; Jordi Sintes; Rodrigo Naves; Kevin S Cashman; José Alberola-Ila; Manel Ramos-Casals; Gloria Soldevila; Chander Raman; Jesús Merino; Ramón Merino; Pablo Engel; Francisco Lozano
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

9.  Immunomodulatory effects of soluble CD5 on experimental tumor models.

Authors:  Inês T Simões; Fernando Aranda; Esther Carreras; Maria Velasco-de Andrés; Sergi Casadó-Llombart; Vanesa G Martinez; Francisco Lozano
Journal:  Oncotarget       Date:  2017-11-20

10.  T-cell modulatory properties of CD5 and its role in antitumor immune responses.

Authors:  Mouna Tabbekh; M'barka Mokrani-Hammani; Georges Bismuth; Fathia Mami-Chouaib
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.